Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Receivables (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Change in Receivables for 16 consecutive years, with $210000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 35.48% to $210000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$693000.0, a 70.66% increase, with the full-year FY2024 number at -$974000.0, down 20.25% from a year prior.
  • Change in Receivables was $210000.0 for Q3 2025 at Harvard Bioscience, up from -$1.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.6 million in Q4 2021 to a low of -$2.8 million in Q2 2024.
  • A 5-year average of -$278526.3 and a median of -$584000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 210.53% in 2021, then tumbled 897.32% in 2022.
  • Harvard Bioscience's Change in Receivables stood at $3.6 million in 2021, then plummeted by 64.12% to $1.3 million in 2022, then dropped by 26.48% to $941000.0 in 2023, then surged by 147.5% to $2.3 million in 2024, then tumbled by 90.98% to $210000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Change in Receivables are $210000.0 (Q3 2025), -$1.8 million (Q2 2025), and -$1.4 million (Q1 2025).